Sequenom snatches up prenatal testing intellectual property; German team spots new thyroid cancer biomarker;

> Sequenom ($SQNM) paid close to $14.6 million for intellectual property from Isis Innovation involving noninvasive prenatal testing. Story (reg. req.)

> Biocept ($BIOC) is expanding its ovarian cancer diagnostics collaboration with MD Anderson Cancer Center. Release

> GE ($GE) named John Flannery as president and CEO of GE Healthcare; Flannery used to be the SVP of business development at the company. Story

> German scientists have identified a new biomarker that points to a cause of thyroid cancer. Item

> Massachusetts Institute of Technology and Tufts University researchers developed a new assay that generates its own synthetic biomarkers to help spot harmful blood clots in mice. Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.